SCHEDULE 13G/A: Foresite Capital Boosts Lyell Immunopharma Stake to 7.6%

Foresite Capital and its affiliates, led by James Tananbaum, reported a combined beneficial ownership of 7.6% in Lyell Immunopharma, Inc. as of September 30, 2025.

Summary

• Foresite Capital Fund IV, L.P. beneficially owns 800,339 shares of Lyell Immunopharma, Inc. common stock, representing 4.2% of the class.
• Foresite Capital Management IV, LLC, as the general partner of Foresite Capital Fund IV, L.P., is deemed to have sole voting and dispositive power over these 800,339 shares.
• Foresite Capital Fund V, L.P. beneficially owns 477,078 shares of Lyell Immunopharma, Inc. common stock, representing 2.5% of the class.
• Foresite Capital Management V, LLC, as the general partner of Foresite Capital Fund V, L.P., is deemed to have sole voting and dispositive power over these 477,078 shares.
• Foresite Capital Opportunity Fund V, L.P. beneficially owns 177,199 shares of Lyell Immunopharma, Inc. common stock, representing 0.9% of the class.
• Foresite Capital Opportunity Management V, LLC, as the general partner of Foresite Capital Opportunity Fund V, L.P., is deemed to have sole voting and dispositive power over these 177,199 shares.
• James Tananbaum, as the managing member of the general partners for all three Foresite Capital funds, is deemed to have sole voting and dispositive power over an aggregate of 1,454,616 shares, representing 7.6% of Lyell Immunopharma, Inc.'s common stock.
• The reported percentages are calculated based on 19,211,202 common shares outstanding of Lyell Immunopharma, Inc. as of August 7, 2025, as disclosed in the Issuer's Form 10-Q filed on August 12, 2025.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine disclosure of beneficial ownership. The maintenance of a significant stake by an institutional investor could be seen as a positive signal, but the filing itself provides no new performance or strategic information.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment firm, Foresite Capital, maintains a substantial stake in Lyell Immunopharma, a biotechnology company. Such disclosures are common for investment funds that cross beneficial ownership thresholds, providing transparency on major shareholders. Foresite Capital specializes in healthcare and life sciences, suggesting their investment aligns with their sector focus.

Related Party Transactions

• Foresite Capital Management IV, LLC is the general partner of Foresite Capital Fund IV, L.P.
• Foresite Capital Management V, LLC is the general partner of Foresite Capital Fund V, L.P.
• Foresite Capital Opportunity Management V, LLC is the general partner of Foresite Capital Opportunity Fund V, L.P.
• James Tananbaum is the managing member of Foresite Capital Management IV, LLC, Foresite Capital Management V, LLC, and Foresite Capital Opportunity Management V, LLC, thereby having indirect control over the shares held by the respective funds.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and potentially voting power in corporate matters.
• Management: Awareness of a significant institutional holder like Foresite Capital may influence strategic decisions or engagement with major investors.

Key Dates

Keywords

Lyell Immunopharma, Foresite Capital, James Tananbaum, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Investment Fund